Specialty Pharmacy

The FDA has approved lusutrombopag (Mulpleta) for the treatment of thrombocytopenia in particular adults with chronic liver disease.

Interferon regulatory factor 2 binding protein-like gene is essential for neurological development and maintenance.

Top news of the day from across the health care landscape.

Jesse C. Dresser, JD, Partner, Frier & Levitt, LLC, discusses laws that help specialty pharmacies access restricted pharmacy networks.

Hepatitis B virus core inhibitor under evaluation in a pair of global phase 2a proof of concept studies.

The FDA has approved iobenguane I-131 (Azedra) for adult and pediatric patients aged ≥12 years with iobenguane scan–positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.

Top news of the day from across the health care landscape.

Study finds that several multiple sclerosis drug candidates inhibit the same enzyme to stimulate myelin regeneration.

Risperidone (Perseris, Indivior) is the first once-monthly subcutaneous risperidone-containing, long-acting injectable for the treatment of schizophrenia in adults.

Study evaluates doravirine once daily compared with ritonavir-boosted darunavir, each taken in combination with other antiretroviral agents.

Blocking the protein receptor, muscarinic type 3, may be effective in promoting remyelination in patients with multiple sclerosis.

Top news of the day from across the health care landscape.

Achilles Alon, PharmD, RPh, director of Specialty Pharmacy, co-owner of ACE-Rx Specialty Pharmacy, discusses some of the challenges in treating patients who acquired hepatitis C virus from injection drug use.

Study investigates complementary medicine use in patients with curable cancer types and its impact on survival and adherence to conventional therapy.

A look at last week's top stories in the world of pharmacy.

Top news of the week from Specialty Pharmacy Times.

As people living with HIV now have a normal life expectancy, the burden of comorbidities is on the rise, and more than half of deaths in the patient population are attributable to the these comorbidities.

Top news of the day from across the health care landscape.

Nationwide analysis of Truvada for pre-exposure prophylaxis use finds uptake associated with significant decrease in new HIV infections.

Study examines the relationship between drinking artificially sweetened beverages and colon cancer disease recurrence and death.

KEYNOTE-048 has met a primary end point of overall survival.

Achilles Alon, PharmD, RPh, Director of Specialty Pharmacy, Co-owner of ACE-Rx Specialty Pharmacy, discusses the importance of pharmacists when treating patients with specialty medications.

Using targeted therapies in patients with gliobastoma who have the mutation may reduce tumor growth and improve survival outcomes.

Researchers estimated whether a hepatitis C vaccine could reduce transmission of the virus among injection drug users, even without providing complete immunity.

A new study suggests that pre-exposure prophylaxis (PrEP) could also serve as a gateway to primary care services.

Top news of the day from across the health care landscape.

Study examining the metabolic pathway points to existing therapies that may slow the growth of small cell lung cancer.

Officials with the FDA have approved elagolix (Orilissa, AbbVie), a product specifically developed for women with moderate to severe endometriosis pain.

Adding acetazolamide to chemotherapy temozolomide for glioblastoma increased sensitivity to treatment and improved survival in animal models.

Study establishes increased risk of all-site cancer for both men and women with diabetes, but the excess risk of cancer is greater for women.